Cargando…

Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC

SIMPLE SUMMARY: Intratumoral hypoxia is a negative prognostic factor in breast cancer progression and recurrence. By implementing a hypoxia fate-mapping system, we followed cells that experience intratumoral hypoxia in vivo and determined that these cells have an increased ability to metastasize com...

Descripción completa

Detalles Bibliográficos
Autores principales: Godet, Inês, Mamo, Mahelet, Thurnheer, Andrea, Rosen, D. Marc, Gilkes, Daniele M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583122/
https://www.ncbi.nlm.nih.gov/pubmed/34771673
http://dx.doi.org/10.3390/cancers13215509
_version_ 1784597141972320256
author Godet, Inês
Mamo, Mahelet
Thurnheer, Andrea
Rosen, D. Marc
Gilkes, Daniele M.
author_facet Godet, Inês
Mamo, Mahelet
Thurnheer, Andrea
Rosen, D. Marc
Gilkes, Daniele M.
author_sort Godet, Inês
collection PubMed
description SIMPLE SUMMARY: Intratumoral hypoxia is a negative prognostic factor in breast cancer progression and recurrence. By implementing a hypoxia fate-mapping system, we followed cells that experience intratumoral hypoxia in vivo and determined that these cells have an increased ability to metastasize compared to cells that were never exposed to hypoxia. In this work, we investigate whether cells that experienced intratumoral hypoxia are also resistant to chemotherapy. By utilizing both in vivo and ex vivo models, we conclude that metastatic cells found in the lung and liver, that were exposed to hypoxia in the primary tumor, are less sensitive to doxorubicin and paclitaxel and drive recurrence after treatment. Our studies also suggest that chemoresistance is associated with a cancer stem cell-like phenotype that is maintained in post-hypoxic cells. ABSTRACT: Hypoxia occurs in 90% of solid tumors and is associated with treatment failure, relapse, and mortality. HIF-1α signaling promotes resistance to chemotherapy in cancer cell lines and murine models via multiple mechanisms including the enrichment of breast cancer stem cells (BCSCs). In this work, we utilize a hypoxia fate-mapping system to determine whether triple-negative breast cancer (TNBC) cells that experience hypoxia in the primary tumor are resistant to chemotherapy at sites of metastasis. Using two orthotopic mouse models of TNBC, we demonstrate that cells that experience intratumoral hypoxia and metastasize to the lung and liver have decreased sensitivity to doxorubicin and paclitaxel but not cisplatin or 5-FU. Resistance to therapy leads to metastatic recurrence caused by post-hypoxic cells. We further determined that the post-hypoxic cells that metastasize are enriched in pathways related to cancer stem cell gene expression. Overall, our results show that even when hypoxic cancer cells are reoxygenated in the bloodstream they retain a hypoxia-induced cancer stem cell-like phenotype that persists and promotes resistance and eventually recurrence.
format Online
Article
Text
id pubmed-8583122
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85831222021-11-12 Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC Godet, Inês Mamo, Mahelet Thurnheer, Andrea Rosen, D. Marc Gilkes, Daniele M. Cancers (Basel) Article SIMPLE SUMMARY: Intratumoral hypoxia is a negative prognostic factor in breast cancer progression and recurrence. By implementing a hypoxia fate-mapping system, we followed cells that experience intratumoral hypoxia in vivo and determined that these cells have an increased ability to metastasize compared to cells that were never exposed to hypoxia. In this work, we investigate whether cells that experienced intratumoral hypoxia are also resistant to chemotherapy. By utilizing both in vivo and ex vivo models, we conclude that metastatic cells found in the lung and liver, that were exposed to hypoxia in the primary tumor, are less sensitive to doxorubicin and paclitaxel and drive recurrence after treatment. Our studies also suggest that chemoresistance is associated with a cancer stem cell-like phenotype that is maintained in post-hypoxic cells. ABSTRACT: Hypoxia occurs in 90% of solid tumors and is associated with treatment failure, relapse, and mortality. HIF-1α signaling promotes resistance to chemotherapy in cancer cell lines and murine models via multiple mechanisms including the enrichment of breast cancer stem cells (BCSCs). In this work, we utilize a hypoxia fate-mapping system to determine whether triple-negative breast cancer (TNBC) cells that experience hypoxia in the primary tumor are resistant to chemotherapy at sites of metastasis. Using two orthotopic mouse models of TNBC, we demonstrate that cells that experience intratumoral hypoxia and metastasize to the lung and liver have decreased sensitivity to doxorubicin and paclitaxel but not cisplatin or 5-FU. Resistance to therapy leads to metastatic recurrence caused by post-hypoxic cells. We further determined that the post-hypoxic cells that metastasize are enriched in pathways related to cancer stem cell gene expression. Overall, our results show that even when hypoxic cancer cells are reoxygenated in the bloodstream they retain a hypoxia-induced cancer stem cell-like phenotype that persists and promotes resistance and eventually recurrence. MDPI 2021-11-02 /pmc/articles/PMC8583122/ /pubmed/34771673 http://dx.doi.org/10.3390/cancers13215509 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Godet, Inês
Mamo, Mahelet
Thurnheer, Andrea
Rosen, D. Marc
Gilkes, Daniele M.
Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC
title Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC
title_full Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC
title_fullStr Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC
title_full_unstemmed Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC
title_short Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC
title_sort post-hypoxic cells promote metastatic recurrence after chemotherapy treatment in tnbc
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583122/
https://www.ncbi.nlm.nih.gov/pubmed/34771673
http://dx.doi.org/10.3390/cancers13215509
work_keys_str_mv AT godetines posthypoxiccellspromotemetastaticrecurrenceafterchemotherapytreatmentintnbc
AT mamomahelet posthypoxiccellspromotemetastaticrecurrenceafterchemotherapytreatmentintnbc
AT thurnheerandrea posthypoxiccellspromotemetastaticrecurrenceafterchemotherapytreatmentintnbc
AT rosendmarc posthypoxiccellspromotemetastaticrecurrenceafterchemotherapytreatmentintnbc
AT gilkesdanielem posthypoxiccellspromotemetastaticrecurrenceafterchemotherapytreatmentintnbc